Our healthcare world is full of examples for how AI could be – or is already – improving diagnosis, treatment, follow up and the overall patient experience.
So, what if AI algorithms were used to make recommendations for treatment decisions, to support doctors in decision-making?
This ‘what if’ scenario begs the question: on which data would this recommendation be made?
One would think it’d be a mix of clinical trial data, real-world evidence and medical guidelines, but new medications arriving in the market would rely entirely on their clinical trial data, and how this is perceived and evaluated by the algorithms. What would this mean for shaping the clinical trial approach?
Experts weighed in on this topic at our recent webinar, including Agathe Acchiardo, a leading health trends and futures expert, Eydith Comenencia Ortiz, a patient experience and insights expert, and Branding Science’s Chris Recaldin and Lucy Ireland.
Key talking points included:
- What will make new medications stand out for the algorithms?
- What changes will be needed in real world and trial data to allow these algorithms to work effectively?
- How will this impact your evidence generation strategy?
For a roundup of their key talking points, click here to read our latest article.
Missed the webinar? No problem. You can watch it in full on demand by clicking here.
Get in touch
Chris Recaldin, Director: [email protected]
Lucy Ireland, Senior Client Services Director: [email protected]
Agathe Acchiardo, Founder, Think Next: [email protected]
Eydith Comenencia Ortiz, Founder & CEO, Conecta Partners: [email protected]